If you have been reading about Tesamorelin and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-02-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Once reconstituted, the peptide is handled as a solution and is less stable than the lyophilized powder. Aqueous solutions are commonly kept cold and used within a defined period. Buffer composition and pH influence degradation rates, with extremes of acidity or alkalinity accelerating hydrolysis. Preservatives may be added in multi-dose formats to limit microbial growth. Freezing and thawing of solutions is generally avoided because it can cause precipitation or loss of activity.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Stability testing examines how the molecule changes under controlled stress. Thermal stress, light exposure, and extremes of pH are applied separately so that each degradation route can be attributed to a specific cause. The main observed changes are oxidation, deamidation, and aggregation into dimers or higher-order species. Accelerated studies at elevated temperature are used to estimate behavior over longer periods, though such extrapolation carries uncertainty. For a lyophilized powder, residual moisture and the choice of bulking agent strongly influence how quickly these changes appear.
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
=== Relative utilization === Due to experimental limitations BV is often measured relative to an easily utilizable protein. Normally egg protein is assumed to be the most readily utilizable protein and given a BV of 100. For example: Two tests of BV are carried out on the same person; one with the test protein source and one with a reference protein (egg protein).
The pitot tube and static port on an aircraft are used to determine the airspeed of the aircraft. These two devices are connected to the airspeed indicator, which determines the dynamic pressure of the airflow past the aircraft. Bernoulli's principle is used to calibrate the airspeed indicator so that it displays the indicated airspeed appropriate to the dynamic pressure. A De Laval nozzle utilizes Bernoulli's principle to create a force by turning pressure energy generated by the combustion of propellants into velocity. This then generates thrust by way of Newton's third law of motion. The flow speed of a fluid can be measured using a device such as a Venturi meter or an orifice plate, which can be placed into a pipeline to reduce the diameter of the flow. For a horizontal device, the continuity equation shows that for an incompressible fluid, the reduction in diameter will cause an increase in the fluid flow speed. Subsequently, Bernoulli's principle then shows that there must be a decrease in the pressure in the reduced diameter region. This phenomenon is known as the Venturi effect. The maximum possible drain rate for a tank with a hole or tap at the base can be calculated directly from Bernoulli's equation and is found to be proportional to the square root of the height of the fluid in the tank. This is Torricelli's law, which is compatible with Bernoulli's principle. Increased viscosity lowers this drain rate; this is reflected in the discharge coefficient, which is a function of the Reynolds number and the shape of the orifice.
== Synthesis of GnSAF == GnSAF is produced in the granulosa cells of the small sized antral follicles, which have the highest concentration of GnSAF. Concentrations of GnSAF bioactivity is inversely proportional to follicle size. Upon synthesis, GnSAF is released into peripheral circulation. Follicle-stimulating hormone (FSH) from the anterior pituitary stimulates and prolongs GnSAF biosynthesis in growing small antral follicles in the ovary. FSH induces expression and transcription of exons 12 and 13 of the HSA gene found in granulosa cells. During the early and mid-follicular phase, FSH is secreted to promote growth and proliferation of the granulosa cells, which increases GnSAF concentrations. Once the dominant ovarian follicle has been selected at mid-follicular phase, the non-dominant follicles undergo atresia. Without the presence of small follicles during the late follicular phase, GnSAF concentrations steadily decline to its lowest levels observable in the ovarian cycle. Additionally, the rate of GnSAF biosynthesis by the granulosa cells of the remaining dominant follicle decreases as the follicle approaches maturation. During the transition between luteal phase and follicular phase, GnSAF gradually increases from the late luteal phase and onwards due to the recruitment of follicles and concomitant rise of FSH. The time-course production of GnSAF depends on the serum FSH concentrations. Higher serum concentrations of FSH increases the potency of the attenuating effects of GnSAF on release of LH.
== Excipient == Excipient has a significant impact on the final product performance, manufacturability, and stability. Therefore, the selection of excipients has to be carefully considered during topical cream formulation design.
Sources: en.wikipedia.org
Methylestradiol, or 17α-methylestradiol (17α-ME), also known as 17α-methylestra-1,3,5(10)-triene-3,17β-diol, is a synthetic estrane steroid and a derivative of estradiol. It is specifically the derivative of estradiol with a methyl group at the C17α positions. Closely related steroids include ethinylestradiol (17α-ethynylestradiol) and ethylestradiol (17α-ethylestradiol). The C3 cyclopentyl ether of methylestradiol has been studied and shows greater oral potency than methylestradiol in animals, similarly to quinestrol (ethinylestradiol 3-cyclopentyl ether) and quinestradol (estriol 3-cyclopentyl ether).
== Frequency == BED is the most common eating disorder, with 47% of people with eating disorders having BED, 3% of them have anorexia nervosa, and 12% of them have bulimia nervosa. Over 57% of people with BED are female and it often begins in the late teens or early 20s.
Iron supplementation by mouth commonly causes negative gastrointestinal effects, including constipation, nausea, vomiting, metallic taste to the oral iron and dark colored stools. Constipation is reported by 15–20% of patients taking oral iron therapy. Preparations of iron therapy that take longer to be absorbed by the small intestine (extended release iron therapy) are less likely to cause constipation. It can take six months to one year to get blood levels of iron up to a normal range and provide the body with iron stores. Oral iron replacement may not be effective in cases of iron deficiency due to malabsorption, such as celiac disease, inflammatory bowel disease, or H. pylori infection; these cases would require treatment of the underlying disease to increase oral absorption or intravenous iron replacement. As iron-deficiency anemia becomes more severe, if the anemia does not respond to oral treatments or if the treated person does not tolerate oral iron supplementation, then other measures may become necessary. Two options are intravenous iron injections and blood transfusion. Intravenous can be for people who do not tolerate oral iron, who are unlikely to respond to oral iron, or who require iron on a long-term basis. For example, people receiving dialysis treatment who are also getting erythropoietin or another erythropoiesis-stimulating agent are given parenteral iron, which helps the body respond to the erythropoietin agents to produce red blood cells.
=== Adults === The special symptom of OSA syndrome in adults is excessive daytime sleepiness. Typically, an adult or adolescent with severe long-standing OSA will fall asleep for very brief periods in the course of usual daytime activities if allowed to sit or rest. This behavior may be quite dramatic, sometimes occurring during conversations with others at social gatherings. The hypoxia (absence of oxygen supply) related to OSA may cause changes in the neurons of the hippocampus and the right frontal cortex. Neuroimaging research revealed evidence of hippocampal atrophy in people with OSA. They found that OSA can cause problems in mentally manipulating nonverbal information, executive functions, and working memory. OSA may also be associated with an increased risk of a person developing Alzheimer's disease. Obesity is a major risk factor for OSA. In the severely obese, the risk for sleep apnea can be between 55 and 90%. However between 20 and 25% of patients with sleep apnea are not overweight. What is often unrecognized in primary care is that it is crucial to identify these patients because they are four times more likely to develop hypertension than obese individuals without OSA. And non-obese patients are at a higher risk for early atherosclerosis. In fact, approximately 2.7 times more than obese patients without OSA. This risk increases as the severity of the syndrome worsens.
=== Non-medical use === Though not an approved drug, LGD-4033 (Ligandrol) has been sold on the black market as a designer drug in countries where it is classified as an illegal substance. Along with enobosarm (ostarine; GTx-024, S-22), andarine (GTx-007; S-4), and vosilasarm (RAD140; "testolone"), LGD-4033 is one of the most popular and common non-medically-used SARMs. Many products sold online that are purported to be LGD-4033 either contain none or contain other unrelated substances, and doses are also frequently not as labeled. Social media has played an important role in facilitating the widespread non-medical use of SARMs. On 23 October 2017, a nutritional supplement company in Missouri called Infantry Labs was warned by the FDA that the distribution of two of its products violated the Federal Food, Drug, and Cosmetic Act. One of the substances was LGD-4033. The company advertised as benefits of the LGD-4033: "increases in lean body mass and decrease in body fat" and "increases in strength, well being, as well as healing possibilities". The company mislabeled as "dietary supplements" what should have been "new drugs" or "prescription drugs" and were instructed to document the steps they would take in order to cease the violation. Also on 23 October 2017, the FDA sent a warning letter to a New Jersey company called Panther Sports Nutrition. The company's marketing approach for the product was similar to that of the Infantry Labs case, and the product was advertised as a "mass builder" and "physique enhancing agent".
Sources: en.wikipedia.org
== Global Research Infrastructure == Widespread interest and funding for research on regenerative medicine has prompted institutions in the United States and around the world to establish departments and research institutes that specialize in regenerative medicine including: The Department of Rehabilitation and Regenerative Medicine at Columbia University, the Institute for Stem Cell Biology and Regenerative Medicine at Stanford University, the Center for Regenerative and Nanomedicine at Northwestern University, the Wake Forest Institute for Regenerative Medicine, and the British Heart Foundation Centers of Regenerative Medicine at the University of Oxford. In China, institutes dedicated to regenerative medicine are run by the Chinese Academy of Sciences, Tsinghua University, and the Chinese University of Hong Kong, among others.
=== Renaming === The laboratory was renamed Lawrence Livermore Laboratory (LLL) in 1971. On October 1, 2007 Lawrence Livermore National Security, LLC (LLNS) assumed management of LLNL from the University of California, which had exclusively managed and operated the Laboratory since its inception 55 years before. The laboratory was honored in 2012 by having the synthetic chemical element livermorium named after it. The LLNS takeover of the laboratory has been controversial. In May 2013, an Alameda County jury awarded over $2.7 million to five former laboratory employees who were among 430 employees LLNS laid off during 2008. The jury found that LLNS breached a contractual obligation to terminate the employees only for "reasonable cause." The five plaintiffs also have pending age discrimination claims against LLNS, which will be heard by a different jury in a separate trial. There are 125 co-plaintiffs awaiting trial on similar claims against LLNS. The May 2008 layoff was the first layoff at the laboratory in nearly 40 years. On March 14, 2011, the City of Livermore officially expanded the city's boundaries to annex LLNL and move it within the city limits. The unanimous vote by the Livermore city council expanded Livermore's southeastern boundaries to cover 15 land parcels covering 1,057 acres (4.28 km2) that comprise the LLNL site. The site was formerly an unincorporated area of Alameda County. The LLNL campus continues to be owned by the federal government.
Troika, unable to obtain further funding from Activision or other publishers, released its employees in two waves: the first in November 2004, followed by the remaining staff in December, except for its three founders, Anderson, Boyarsky, and Tim Cain. Some employees worked without pay to fix the game. When the company closed in February 2005, it had secured no other game development deals. That month, Boyarsky confirmed that Troika had not been working on a patch for the game since most of its staff had been gone since December 2004. In a 2006 interview, Anderson said that although Troika Games's library had been critically well received, consistent technical issues had marred the perception of the company's games, contributing to Troika's difficulty in obtaining new projects. In 2013, Mitsoda said that Bloodlines was released at "the worst possible time - most people didn't even know we were out ... fans and the Troika [developers] are always going to wonder what the game could have been like with another six months." In a 2017 interview, Boyarsky echoed Mitsoda's sentiments, saying that a further three to six months of development time could have allowed Troika to address many technical flaws, but he was unsure that they could have resolved larger issues. He said, "I feel the second half of the game isn't as good as the first. I feel like we devolved into relying too much on combat at the end." Boyarsky noted that it was impossible to know if the fixes would have made Bloodlines more successful or if it would have remained a niche product.
== History == It was developed by Boehringer Ingelheim, patented in 2005, and is co-marketed by Eli Lilly and Company. For cardiovascular death, the FDA based its decision on a postmarketing study it required when it approved empagliflozin in 2014, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Empagliflozin was studied in a postmarket clinical trial of more than 7,000 participants with type 2 diabetes and cardiovascular disease. In the trial, empagliflozin was shown to reduce the risk of cardiovascular death compared to a placebo when added to standard of care therapies for diabetes and atherosclerotic cardiovascular disease. For heart failure, the safety and effectiveness of empagliflozin were evaluated by the FDA as an adjunct to standard of care therapy in a randomized, double-blind, international trial comparing 2,997 participants who received empagliflozin, 10 mg, once daily to 2,991 participants who received the placebo. The main efficacy measurement was the time to death from cardiovascular causes or need to be hospitalized for heart failure. Of the individuals who received empagliflozin for an average of about two years, 14% died from cardiovascular causes or were hospitalized for heart failure, compared to 17% of the participants who received the placebo. This benefit was mostly attributable to fewer participants being hospitalized for heart failure. The FDA granted the application for empagliflozin priority review, and approved the additional indication of heart failure in 2022.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
Refrigeration between 2 and 8 degrees Celsius is typical, with protection from moisture and light. Dry, sealed containers help maintain stability over the labeled shelf life. Temperature cycling is usually minimized.